Incyte (NASDAQ:INCY) Stock: Insider Thomas Tray Sells 610 Shares

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 610 shares of Incyte stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the transaction, the insider directly owned 21,126 shares in the company, valued at $2,513,148.96. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Incyte Stock Up 1.4%

Shares of INCY opened at $119.65 on Friday. The company has a market capitalization of $24.39 billion, a PE ratio of 56.62, a price-to-earnings-growth ratio of 4.50 and a beta of 0.78. The stock has a fifty day simple moving average of $119.62 and a two-hundred day simple moving average of $108.51. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. The firm had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm’s revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.26 EPS. As a group, equities analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INCY. Allworth Financial LP lifted its stake in shares of Incyte by 4.2% in the 3rd quarter. Allworth Financial LP now owns 5,402 shares of the biopharmaceutical company’s stock worth $612,000 after acquiring an additional 220 shares during the period. Fisher Asset Management LLC raised its holdings in Incyte by 6.1% during the 3rd quarter. Fisher Asset Management LLC now owns 145,442 shares of the biopharmaceutical company’s stock worth $17,649,000 after purchasing an additional 8,424 shares during the last quarter. Legacy Trust raised its holdings in Incyte by 2.9% during the 3rd quarter. Legacy Trust now owns 39,016 shares of the biopharmaceutical company’s stock worth $4,697,000 after buying an additional 1,089 shares during the period. Fifth Third Bancorp raised its holdings in shares of Incyte by 7.6% in the 3rd quarter. Fifth Third Bancorp now owns 29,647 shares of the biopharmaceutical company’s stock valued at $3,598,000 after purchasing an additional 2,090 shares during the period. Finally, Maryland State Retirement & Pension System increased its holdings in shares of Incyte by 12.4% during the third quarter. Maryland State Retirement & Pension System now owns 9,790 shares of the biopharmaceutical company’s stock worth $1,188,000 after purchasing an additional 1,081 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Piper Sandler raised their price objective on shares of Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Raymond James Financial set a $152.00 target price on Incyte in a report on Friday, October 16th. Mizuho lifted their target price on shares of Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. UBS Group set a $152.00 price objective on Incyte in a report on Friday, October 30th. Finally, Leerink Partners lowered their price target on shares of Incyte from $154.00 to $150.00 and set an “outperform” rating on the stock in a report on Thursday. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $132.86.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.